2021 CMSC Annual Meeting

Tag: (2)Neurology

Poster-Quality of Life and Outcomes

The Importance of Specialty Pharmacy Services in Multiple Sclerosis Patient Care

Background: Johns Hopkins Specialty Pharmacy provides clinical services for eligible multiple sclerosis (MS) patients on oral and...

Read More

Poster-Quality of Life and Outcomes

An Update on Participants in the Iconquerms Network.

Background: iConquerMS is a multiple sclerosis (MS) participant-powered research network (PPRN), dedicated to engaging people affected by...

Read More

Poster-Neurophysiology; Neuropsychology and Neuropsychiatry

Longitudinal Olfactory Patterns in Multiple Sclerosis: A Scoping Review and Implications for Use in Management of Disease

Background: Previous studies reviewing the presence of olfactory dysfunction (OD) in Multiple Sclerosis (MS) have focused on the prevalence...

Read More

Poster-Programs

The Influence of Tethered and Joint HCP and Patient Education on Clinical Practice Behavior, Patient Activation, and Empowerment

Background: Advances in disease-modifying therapies (DMT) for multiple sclerosis (MS) have left clinicians challenged to incorporate DMTs,...

Read More

Poster-Neurophysiology; Neuropsychology and Neuropsychiatry

Stability of the Gut Microbiota in Persons with Pediatric-Onset Multiple Sclerosis and Related Demyelinating Diseases

Background: Little is known about the stability of the gut microbiota in multiple sclerosis (MS) over time. Objectives: To determine...

Read More

Poster-Non-imaging Biomarkers

Predicting Stress Levels and Response to a Self-Management Program Using Participant Demographic, Clinical, and Biomarker Data: A Secondary Analysis

Background: Stress management techniques are actively being pursued for multiple sclerosis (MS); the utility of biomarkers for predicting...

Read More

Poster-Disease-modifying Therapy

The Benefits of Azathioprine in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: A Systematic Review and Meta-Analysis

Background: MOGAD is an emerging inflammatory demyelination disorder of the central nervous system. AZA is one of the commonly used...

Read More

Poster-Disease-modifying Therapy

Is There ‘Wearing Off’ with Ocrelizumab? Preliminary Results of Symptom Burden on Ocrelizumab, a Longitudinal Study (SymBOLS).

Background: Ocrelizumab (OCR), a humanized, anti-CD20 antibody therapy approved for multiple sclerosis (MS), is given at 6-month intervals....

Read More

Poster-Disease-modifying Therapy

Characteristics and Outcome of COVID-19 in Patients with Relapsing Multiple Sclerosis Receiving Ofatumumab

Background: A global pandemic of COVID-19 has resulted in over 78 million cases as of 23 December 2020. Risks of …...

Read More

Poster-Disease-modifying Therapy

Analysis of Health Care Provider Reasons for Switching to Diroximel Fumarate from Other Disease-Modifying Therapies

Background: Switching of disease-modifying therapies (DMTs) for treatment of multiple sclerosis (MS) is driven by many factors that are not...

Read More